Thermo Fisher streamlines its portfolio with a $1B+ microbiology sale to Astorg

📌 Thermo Fisher has reached an agreement to sell its microbiology business to Astorg for around $1.075–$1.08 billion, including a $50 million seller note. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.
🔎 The business sits under Specialty Diagnostics, focusing on antimicrobial susceptibility testing and culture media for clinical, pharmaceutical, and food safety applications. It generated around $645 million in revenue in 2025, implying a valuation of nearly 1.7 times revenue.
💡 For Thermo Fisher, the deal reflects a continued effort to streamline its portfolio and redeploy capital toward higher-growth areas. The near-term impact is not large, but the company expects adjusted EPS dilution of about $0.15 in the first full year after closing.
⚖️ For Astorg, this is a healthcare asset with stable cash flow that can be carved out into an independent platform for further expansion. Market reaction is likely to stay neutral, as the deal looks more like portfolio restructuring than an immediate earnings catalyst.
#Healthcare #MarketInsights